Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular disease
Pharma
Novo's oral GLP-1 Rybelsus cuts heart disease risks
The FDA has accepted Novo Nordisk’s application for a label expansion for its oral GLP-1 drug Rybelsus to reduce the risk of cardiovascular events.
Kevin Dunleavy
Mar 31, 2025 11:30am
Bayer brings heart health message to the Super Bowl
Feb 11, 2025 9:00am
AstraZeneca-CSPC, Astellas and more—Fierce Pharma Asia
Oct 11, 2024 9:48am
Silence Therapeutics gets loud in Lp(a) awareness campaign
Aug 29, 2024 8:30am
Pfizer's ATTR drug needs hefty discount, says ICER draft report
Jul 18, 2024 4:37pm
Alnylam touts 'big-win scenario' for closely watched heart trial
Jun 24, 2024 10:53am
